Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287266 | 0.82 | HTR2A (0.60) | GRM5HTR2AHTR2CHTR2BCHRM4 | |
| SCHEMBL1134458 | 0.78 | HTR2A (0.43) | GRM5GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3266839 | 0.77 | MAOB (0.49) | HTR2AHTR2CHTR2BCHRM4ADRB1 | |
| SCHEMBL3272326 | 0.77 | MAPK1 (0.48) | HTR2AHTR2CHTR2BCHRM4ADRB1 | |
| SCHEMBL22932921 | 0.77 | GRM5 (0.41) | GRM5CYP11B1CYP11B2 | |
| SCHEMBL29664275 | 0.77 | GRM5 (0.41) | GRM5CYP11B1CYP11B2 | |
| SCHEMBL11380119 | 0.77 | GRM5 (0.47) | GRM5HRH3CYP19A1 | |
| SCHEMBL905932 | 0.77 | HTR2C (0.73) | GRM5GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3270680 | 0.76 | FFAR1 (0.44) | GRM5HTR2AHTR2CHTR2BCYP11B1 | |
| SCHEMBL3272689 | 0.76 | GRM5 (0.46) | GRM5HTR2AHTR2CHTR2BCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | GRM5 30/4885MRGPRX4 220/4885GABRG2 283/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | GRM5 30/4885MRGPRX4 220/4885GABRG2 283/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | GRM5 30/4885MRGPRX4 245/4885GABRG2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.